Cargando…
Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study
OBJECTIVES: Human papillomavirus (HPV) positive oropharyngeal cancer (oropharyngeal squamous cell carcinoma, OPSCC) is biologically and clinically different from HPV negative OPSCC. Here, we evaluate the use of a radiomic approach to identify the HPV status of OPSCC. METHODS: Four independent cohort...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Institute of Radiology.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223271/ https://www.ncbi.nlm.nih.gov/pubmed/29451412 http://dx.doi.org/10.1259/bjr.20170498 |
_version_ | 1783369380720017408 |
---|---|
author | Leijenaar, Ralph TH Bogowicz, Marta Jochems, Arthur Hoebers, Frank JP Wesseling, Frederik WR Huang, Sophie H Chan, Biu Waldron, John N O'Sullivan, Brian Rietveld, Derek Leemans, C Rene Brakenhoff, Ruud H Riesterer, Oliver Tanadini-Lang, Stephanie Guckenberger, Matthias Ikenberg, Kristian Lambin, Philippe |
author_facet | Leijenaar, Ralph TH Bogowicz, Marta Jochems, Arthur Hoebers, Frank JP Wesseling, Frederik WR Huang, Sophie H Chan, Biu Waldron, John N O'Sullivan, Brian Rietveld, Derek Leemans, C Rene Brakenhoff, Ruud H Riesterer, Oliver Tanadini-Lang, Stephanie Guckenberger, Matthias Ikenberg, Kristian Lambin, Philippe |
author_sort | Leijenaar, Ralph TH |
collection | PubMed |
description | OBJECTIVES: Human papillomavirus (HPV) positive oropharyngeal cancer (oropharyngeal squamous cell carcinoma, OPSCC) is biologically and clinically different from HPV negative OPSCC. Here, we evaluate the use of a radiomic approach to identify the HPV status of OPSCC. METHODS: Four independent cohorts, totaling 778 OPSCC patients with HPV determined by p16 were collected. We randomly assigned 80% of all data for model training (N = 628) and 20% for validation (N = 150). On the pre-treatment CT images, 902 radiomic features were calculated from the gross tumor volume. Multivariable modeling was performed using least absolute shrinkage and selection operator. To assess the impact of CT artifacts in predicting HPV (p16), a model was developed on all training data (M(all)) and on the artifact-free subset of training data (M(no art)). Models were validated on all validation data (V(all)), and the subgroups with (V(art)) and without (V(no art)) artifacts. Kaplan–Meier survival analysis was performed to compare HPV status based on p16 and radiomic model predictions. RESULTS: The area under the receiver operator curve for M(all) and M(no art) ranged between 0.70 and 0.80 and was not significantly different for all validation data sets. There was a consistent and significant split between survival curves with HPV status determined by p16 [p = 0.007; hazard ratio (HR): 0.46], M(all) (p = 0.036; HR: 0.55) and M(no art) (p = 0.027; HR: 0.49). CONCLUSION: This study provides proof of concept that molecular information can be derived from standard medical images and shows potential for radiomics as imaging biomarker of HPV status. ADVANCES IN KNOWLEDGE: Radiomics has the potential to identify clinically relevant molecular phenotypes. |
format | Online Article Text |
id | pubmed-6223271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | The British Institute of Radiology. |
record_format | MEDLINE/PubMed |
spelling | pubmed-62232712019-06-01 Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study Leijenaar, Ralph TH Bogowicz, Marta Jochems, Arthur Hoebers, Frank JP Wesseling, Frederik WR Huang, Sophie H Chan, Biu Waldron, John N O'Sullivan, Brian Rietveld, Derek Leemans, C Rene Brakenhoff, Ruud H Riesterer, Oliver Tanadini-Lang, Stephanie Guckenberger, Matthias Ikenberg, Kristian Lambin, Philippe Br J Radiol Full Paper OBJECTIVES: Human papillomavirus (HPV) positive oropharyngeal cancer (oropharyngeal squamous cell carcinoma, OPSCC) is biologically and clinically different from HPV negative OPSCC. Here, we evaluate the use of a radiomic approach to identify the HPV status of OPSCC. METHODS: Four independent cohorts, totaling 778 OPSCC patients with HPV determined by p16 were collected. We randomly assigned 80% of all data for model training (N = 628) and 20% for validation (N = 150). On the pre-treatment CT images, 902 radiomic features were calculated from the gross tumor volume. Multivariable modeling was performed using least absolute shrinkage and selection operator. To assess the impact of CT artifacts in predicting HPV (p16), a model was developed on all training data (M(all)) and on the artifact-free subset of training data (M(no art)). Models were validated on all validation data (V(all)), and the subgroups with (V(art)) and without (V(no art)) artifacts. Kaplan–Meier survival analysis was performed to compare HPV status based on p16 and radiomic model predictions. RESULTS: The area under the receiver operator curve for M(all) and M(no art) ranged between 0.70 and 0.80 and was not significantly different for all validation data sets. There was a consistent and significant split between survival curves with HPV status determined by p16 [p = 0.007; hazard ratio (HR): 0.46], M(all) (p = 0.036; HR: 0.55) and M(no art) (p = 0.027; HR: 0.49). CONCLUSION: This study provides proof of concept that molecular information can be derived from standard medical images and shows potential for radiomics as imaging biomarker of HPV status. ADVANCES IN KNOWLEDGE: Radiomics has the potential to identify clinically relevant molecular phenotypes. The British Institute of Radiology. 2018-06 2018-03-21 /pmc/articles/PMC6223271/ /pubmed/29451412 http://dx.doi.org/10.1259/bjr.20170498 Text en © 2018 The Authors. Published by the British Institute of Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 Unported License http://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted non-commercial reuse, provided the original author and source are credited. |
spellingShingle | Full Paper Leijenaar, Ralph TH Bogowicz, Marta Jochems, Arthur Hoebers, Frank JP Wesseling, Frederik WR Huang, Sophie H Chan, Biu Waldron, John N O'Sullivan, Brian Rietveld, Derek Leemans, C Rene Brakenhoff, Ruud H Riesterer, Oliver Tanadini-Lang, Stephanie Guckenberger, Matthias Ikenberg, Kristian Lambin, Philippe Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study |
title | Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study |
title_full | Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study |
title_fullStr | Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study |
title_full_unstemmed | Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study |
title_short | Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study |
title_sort | development and validation of a radiomic signature to predict hpv (p16) status from standard ct imaging: a multicenter study |
topic | Full Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223271/ https://www.ncbi.nlm.nih.gov/pubmed/29451412 http://dx.doi.org/10.1259/bjr.20170498 |
work_keys_str_mv | AT leijenaarralphth developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy AT bogowiczmarta developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy AT jochemsarthur developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy AT hoebersfrankjp developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy AT wesselingfrederikwr developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy AT huangsophieh developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy AT chanbiu developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy AT waldronjohnn developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy AT osullivanbrian developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy AT rietveldderek developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy AT leemanscrene developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy AT brakenhoffruudh developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy AT riestereroliver developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy AT tanadinilangstephanie developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy AT guckenbergermatthias developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy AT ikenbergkristian developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy AT lambinphilippe developmentandvalidationofaradiomicsignaturetopredicthpvp16statusfromstandardctimagingamulticenterstudy |